Mesa Laboratories, Inc. (MLAB) Given Average Rating of “Strong Buy” by Analysts

Mesa Laboratories, Inc. (NASDAQ:MLAB) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus price target of $175.00 for the company and are forecasting that the company will post $0.76 earnings per share for the current quarter, according to Zacks. Zacks has also given Mesa Laboratories an industry rank of 168 out of 265 based on the ratings given to its competitors.

A number of equities research analysts recently issued reports on the stock. TheStreet raised shares of Mesa Laboratories from a “c+” rating to a “b” rating in a research note on Monday, November 6th. Zacks Investment Research downgraded shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research note on Friday, November 10th. Finally, BidaskClub downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th.

In other news, Director John Bradley Schmieder sold 3,000 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the director now owns 77,869 shares of the company’s stock, valued at $10,299,732.63. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 15.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in MLAB. Swiss National Bank raised its stake in shares of Mesa Laboratories by 9.6% in the second quarter. Swiss National Bank now owns 5,702 shares of the medical instruments supplier’s stock valued at $817,000 after acquiring an additional 500 shares during the period. Wells Fargo & Company MN raised its stake in shares of Mesa Laboratories by 19.9% in the second quarter. Wells Fargo & Company MN now owns 3,326 shares of the medical instruments supplier’s stock valued at $476,000 after acquiring an additional 553 shares during the period. Alliancebernstein L.P. raised its stake in shares of Mesa Laboratories by 52.9% in the second quarter. Alliancebernstein L.P. now owns 2,600 shares of the medical instruments supplier’s stock valued at $373,000 after acquiring an additional 900 shares during the period. Teachers Advisors LLC raised its stake in shares of Mesa Laboratories by 14.9% in the second quarter. Teachers Advisors LLC now owns 5,660 shares of the medical instruments supplier’s stock valued at $811,000 after acquiring an additional 733 shares during the period. Finally, TIAA CREF Investment Management LLC raised its stake in shares of Mesa Laboratories by 10.9% in the second quarter. TIAA CREF Investment Management LLC now owns 8,552 shares of the medical instruments supplier’s stock valued at $1,226,000 after acquiring an additional 841 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Shares of Mesa Laboratories (NASDAQ MLAB) opened at $132.53 on Thursday. The stock has a market cap of $499.30, a price-to-earnings ratio of -132.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.64 and a current ratio of 2.37. Mesa Laboratories has a 12 month low of $117.58 and a 12 month high of $169.80.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Wednesday, February 28th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend is Tuesday, February 27th. Mesa Laboratories’s dividend payout ratio is currently -64.00%.

TRADEMARK VIOLATION WARNING: “Mesa Laboratories, Inc. (MLAB) Given Average Rating of “Strong Buy” by Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/15/mesa-laboratories-inc-mlab-given-average-rating-of-strong-buy-by-analysts.html.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply